What MOTS-c is, and the difference between measuring it in people and testing it in people
In short
MOTS-c is a peptide encoded in mitochondrial rather than nuclear DNA. In people, what has been measured is how the peptide already circulating in blood changes; the studies where it is administered are in mice. In that same human study, eight weeks of moderate exercise did not change its levels.
MOTS-c has a feature that makes it genuinely interesting: it is not encoded in nuclear DNA but in mitochondrial DNA. It belongs to a small family of mitochondrially derived peptides discovered relatively recently [4].
The distinction that decides everything else
There is literature in people and literature in mice, and they do not say remotely the same thing.
In mice it is administered. One study injected the peptide into diet-induced obese mice and described changes in three plasma metabolic pathways, along with better insulin sensitivity and less fat accumulation [1]. There the compound comes from outside and the effect is measured.
In people it is measured. The human study located did not administer MOTS-c to anyone: it measured what was already circulating in blood and how it responded to an infusion of lipids and then insulin, in women with polycystic ovary syndrome and in healthy controls [2].
These are two different questions. One is "what does this peptide do if I put it in?" and the other is "how does the one already there behave?". Only the first says anything about what is inside a vial.
What the human study found, in full
- Lipids raise it. The lipid infusion raised plasma MOTS-c in both controls and the polycystic ovary syndrome group, and the subsequent insulin attenuated that response [2].
- And exercise did not move it. After eight weeks of moderate training, there were no changes in circulating levels in either the healthy controls or the syndrome group [2].
That second point deserves underlining because it runs directly against the label this compound is usually sold under. The idea that MOTS-c is an "exercise mimetic" comes from the animal models [1]; in the human study located, exercise did not alter it. A dedicated review of mitochondrially derived peptides and exercise covers the state of that question [3].
What there is not
No clinical trial administering MOTS-c to people has been located, nor any approved indication from any agency.
This page describes published literature. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional.
What to look at when comparing suppliers
- HPLC purity for the specific batch and identity confirmation, with a readable certificate.
- Be wary of anyone citing the mouse results as if they were human. It is the most profitable confusion around this product and the easiest to check: open the paper and see which species it was done in.
- A real cold chain and verified net content of the vial.
References
- [1] Kim S.J. et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. PMID 31293078 View source
- [2] Ramanjaneya M. et al. (2019). Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). PMID 31066084 View source
- [3] Woodhead J.S.T. et al. (2021). Mitochondrial-derived peptides and exercise. Biochim Biophys Acta Gen Subj. PMID 34520826 View source
- [4] Zheng Y. et al. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol. PMID 36761202 View source
This page reports what has been published in the scientific literature about a research molecule. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional. The product is sold strictly for in vitro research.
